Pretax income is the income that a company earns before paying income taxes. Halozyme Therapeutics's pretax income for the
three
months ended in Dec. 2024 was $178 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $557 Mil.
Halozyme Therapeutics's pretax margin was 59.80%.
During the past 13 years, Halozyme Therapeutics's highest Pretax Margin was 56.06%. The lowest was -69.44%. And the median was 28.59%.
Halozyme Therapeutics Pre-Tax Income Historical Data
The historical data trend for Halozyme Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Halozyme Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Halozyme Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $557 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics (NAS:HALO) Pre-Tax Income Explanation
Halozyme Therapeutics's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as
During the past 13 years, Halozyme Therapeutics's highest Pretax Margin was 56.06%. The lowest was -69.44%. And the median was 28.59%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Halozyme Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HALO has been successfully added to your 